A Phase 3 interventional study of Vedolizumab and Vedolizumab placebo in Crohn's Disease, sponsored by Takeda. Completed at 56 sites in Japan. Open to participants aged 15 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-12-09.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing vedolizumab in Crohn Disease — 10 open to participants now, 12 under way, 7 of them phase 3. vedolizumab · Crohn Disease.
Among the 39 studies testing vedolizumab in Crohn Disease, this one is the 16th largest by enrollment, is one of 2 that started in 2014, is one of 16 in phase 3, and was the 6th registered.
1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →10 of the 39 studies testing vedolizumab in Crohn Disease are open now, in 12 countries. Recruiting first, the newest first:
Takeda · Sites in United States, Belgium, Bulgaria and 11 more countries
Ages 2–17
Takeda · Sites in United States
Ages 18–80
Takeda · Sites in United States, Belgium, Bulgaria and 13 more countries
Ages 2–17
Takeda · Sites in United States, Austria, Belgium and 23 more countries
Ages 18–65
Centre Hospitalier Universitaire de Saint Etienne · Sites in France
Ages 18+
By country, each count listing its studies:
vedolizumab: first FDA approval 2014 (ENTYVIO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 15 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 157 is above the median of 67 across 1,261 interventional studies indexed under Crohn Disease.
Median enrollment 101 across the 39 interventional studies. Of the 22 that completed or were terminated, 18 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 39 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
86 studies in Crohn Disease by Takeda: 12 open now, 14 under way, 7 of them phase 3. Of 66 finished, 37 (56%) have results posted.
Among the 86 studies in Crohn Disease by Takeda, this one is the 21st largest by enrollment of the 51 interventional ones that give a count, is one of 2 that started in 2014, is one of 25 in phase 3, and was the 14th registered.
Takeda’s Crohn Disease studies by the year they started, since 2000.
5 of the studies testing vedolizumab in Crohn Disease that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06227910Phase 3TakedaA Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease | 2027-06-08 |
| NCT04779320Phase 3TakedaA Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD) | 2027-09-13 |
| NCT06581328TakedaA Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting | 2027-05-01 |
| NCT06045754TakedaA Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease | 2027-06-28 |
| NCT06180382Centre Hospitalier Universitaire de Saint EtienneComparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration. | 2027-10-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 39 studies testing vedolizumab in Crohn Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 86 in Crohn Disease:
This tab as a report to print or save as PDF → With an account.
This study is a phase 3, multicenter, randomized, double-blinded, placebo-controlled, parallel-group study to examine the efficacy, safety, and pharmacokinetics of vedolizumab (MLN0002) in induction and maintenance therapy in Japanese participants with moderately or severely active Crohn's disease.
This is a phase 3, multicenter, randomized, double-blinded, placebo-controlled, parallel-group study to examine the efficacy, safety, and pharmacokinetics of intravenous vedolizumab (300 mg) infusion in induction and maintenance therapy in Japanese participants with moderately or severely active Crohn's disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants with baseline CDAI score of 220 to 450(inclusive) and meeting at least one of the followings:
Participants meeting the criteria for treatment failure below with at least one of the following agents received within previous 5 year period before giving consent
Immunomodulators (azathioprine, 6-mercaptopurine or methotrexate)
Anti-tumor necrosis factor alpha (TNFα) antibodies
Exclusion Criteria:
Participants who had a complication or a history of . However, this does not apply to the following participants:
Participants who had any of the following laboratory abnormalities at the screening;
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vedolizumab 300 mg, intravenous (IV) infusion, once at Weeks 0, 2 and 6 in the induction phase.
Drug: Vedolizumab
Vedolizumab placebo-matching IV infusion once at Weeks 0, 2 and 6 in the induction phase.
Drug: Vedolizumab placebo
Vedolizumab placebo-matching, IV infusion, once at Weeks 14, 22, 30, 38, 46 and 54 in maintenance phase. Participants received vedolizumab in induction phase and achieved Crohn's Disease Activity Index (CDAI)-70 response at Week 10 and were randomized to receive vedolizumab in maintenance phase.
Drug: Vedolizumab
Vedolizumab placebo-matching, IV infusion, once at Weeks 14, 22, 30, 38, 46 and 54 in maintenance phase. Participants received vedolizumab in induction phase and achieved CDAI-70 response at Week 10 and were randomized to receive placebo in maintenance phase.
Drug: Vedolizumab placebo
Vedolizumab placebo-matching, IV infusion, once at Weeks 14, 22, 30, 38, 46 and 54 in maintenance phase. Participants received vedolizumab placebo-matching in induction phase and achieved CDAI-70 response at Week 10 received placebo in maintenance phase without randomization.
Drug: Vedolizumab placebo
Vedolizumab 300 mg, IV infusion, once at Weeks 0, 2 and 6 and then every 8 weeks thereafter up to Week 94 as a maximum duration in open-label phase.
Drug: Vedolizumab
Vedolizumab IV injection
Also known as: MLN0002
Vedolizumab placebo-matching IV infusion
Induction Phase: Percentage of Participants With Crohn's Disease Activity Index (CDAI)-100 Response
A response to therapy is considered a decrease from baseline of at least 100 points in the CDAI score at Week 10. CDAI is scoring system for the assessment of Crohn's disease activity. The total CDAI score ranges from 0 to approximately 600, where higher scores indicate more severe disease. Index values of 150 and below are associated with quiescent disease; values above that indicate active disease.
Time frame: Week 10
Maintenance Phase: Percentage of Participants With Clinical Remission
Clinical remission is defined as the CDAI score ≤150. CDAI is scoring system for the assessment of Crohn's disease activity. Index values of 150 and below are associated with quiescent disease; values above that indicate active disease.
Time frame: Week 60
Number of Participants Who Experienced at Least One or More Treatment-Emergent Adverse Events (TEAEs)
An Adverse event (AE) is defined as any untoward medical occurrence in a study participant who received a drug (including a study drug); it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug whether or not it is considered related to the drug. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug.
Time frame: From Baseline up to 16 weeks after the last dose of study drug (Up to approximately 170 weeks)
Number of Participants With TEAE Related to Body Weight (Weight Decreased)
Reported events on this outcome measure were "Weight Decreased".
Time frame: From Baseline up to 16 weeks after the last dose of study drug (Up to approximately 170 weeks)
Number of Participants With TEAE Related to Vital Signs
Vital signs included body temperature (axilla), sitting blood pressure (after the participant has rested for at least 5 minutes), and pulse (bpm). Reported events on this outcome measure were "Pyrexia", "Body temperature increased", "Hypertension", and "Orthostatic hypotension".
Time frame: From Baseline up to 16 weeks after the last dose of study drug (Up to approximately 170 weeks)
Number of Participants With TEAE Related to Electrocardiogram (ECG) [Bundle Branch Block Right]
Reported events on this outcome measure were "Bundle Branch Block Right".
Time frame: From Baseline up to 16 weeks after the last dose of study drug (Up to approximately 170 weeks)
Number of Participants With Markedly Abnormal Values of Laboratory Parameters Values
The laboratory values outside the range (Hemoglobin \<=7 g/dL, Lymphocytes \<500 /microL, White Blood Cell (WBC) \<2000 /microL, Platelets \<7.5 10\^4/microL, Neutrophils \<1000 /microL, Alanine Aminotransferase (ALT) (Glutamic Pyruvic Transaminase; GPT) \>3.0 U/L x upper limit of normal (ULN), Aspartate Aminotransferase (AST) (Glutamic Oxaloacetic Transaminase; GOT) \>3.0 U/L x ULN, Total Bilirubin \>2.0 mg/dL x ULN, Amylase \>2.0 (U/L) x ULN are considered markedly abnormal.
Time frame: From Baseline up to 16 weeks after the last dose of study drug (Up to approximately 170 weeks)
Induction Phase: Percentage of Participants With Clinical Remission
Clinical remission is defined as the CDAI score ≤150. CDAI is scoring system for the assessment of Crohn's disease activity. Index values of 150 and below are associated with quiescent disease; values above that indicate active disease.
Time frame: Week 10
Induction Phase: Change From Baseline in C-reactive Protein (CRP) Values
Time frame: Baseline to Week 10
Maintenance Phase: Percentage of Participants With Crohn's Disease Activity Index (CDAI)-100 Response
A response to therapy is considered a decrease from baseline of at least 100 points in the CDAI score at Week 10. CDAI is scoring system for the assessment of Crohn's disease activity. The total CDAI score ranges from 0 to approximately 600, where higher scores indicate more severe disease. Index values of 150 and below are associated with quiescent disease; values above that indicate active disease.
Time frame: Week 60
Maintenance Phase: Percentage of Participants With Durable Clinical Remission
Durable clinical remission is defined as participants with CDAI score ≤ 150 at both Weeks 14 and 60. CDAI is scoring system for the assessment of Crohn's disease activity. The total CDAI score ranges from 0 to approximately 600, where higher scores indicate more severe disease. Index values of 150 and below are associated with quiescent disease; values above that indicate active disease.
Time frame: From Week 14 and Week 60
Maintenance Phase: Percentage of Participants With Corticosteroid-free Clinical Remission
Corticosteroid-free clinical remission is defined as participants using oral corticosteroids at baseline (Week 0) who discontinued corticosteroids and were in clinical remission (CDAI score ≤ 150) at Week 60. CDAI is scoring system for the assessment of Crohn's disease activity. The total CDAI score ranges from 0 to approximately 600, where higher scores indicate more severe disease. Index values of 150 and below are associated with quiescent disease; values above that indicate active disease.
Time frame: Week 60
Serum Vedolizumab Concentration in Induction Phase
Time frame: Weeks 2, 6, 10 and 14
Serum Vedolizumab Concentration in Maintenance Phase
Time frame: Weeks 2, 6, 10, 14, 22, 30 and 60
Number of Participants With Anti-vedolizumab Antibodies (AVA) in Induction Phase
Time frame: Weeks 0, 10 and 16 weeks after the last dose of study drug in induction phase
Number of Participants With Anti-vedolizumab Antibodies (AVA) in Maintenance Phase
Time frame: Weeks 0, 10, 30, 60 and 16 weeks after the last dose of study drug in maintenance phase
Number of Participants With Anti-vedolizumab Antibodies (AVA) in Open Label Cohort
Time frame: Weeks 0, 10, 30, 62, 94 and 16 weeks after the last dose of study drug in open-label cohort
Number of Participants With Neutralizing Anti-vedolizumab Antibodies (AVA) in Induction Phase
Time frame: Weeks 0, 10 and 16 weeks after the last dose of study drug in induction phase
Number of Participants With Neutralizing Anti-vedolizumab Antibodies (AVA) in Maintenance Phase
Time frame: Weeks 0, 10, 30, 60 and 16 weeks after the last dose of study drug in maintenance phase
Number of Participants With Neutralizing Anti-vedolizumab Antibodies (AVA) in Open Label Cohort
Time frame: Weeks 0, 10, 30, 62, 94 and 16 weeks after the last dose of study drug in open-label cohort
Participants took part in the study at 77 investigative sites in Japan from 28 Jan 2014 to 21 May 2019.
| Milestone | Induction Phase: Vedolizumab, 300 mg | Induction Phase: Placebo | Maintenance Phase: Vedolizumab 300 mg | Maintenance Phase: Placebo | Maintenance Phase: Placebo Continuation | Open-Label: Vedolizumab 300 mg |
|---|---|---|---|---|---|---|
| Started | 79 | 78 | 0 | 0 | 0 | 0 |
| Completed | 73 | 66 | 0 | 0 | 0 | 0 |
| Not completed | 6 | 12 | 0 | 0 | 0 | 0 |
| Withdrew: Pretreatment event/adverse event | 3 | 11 | 0 | 0 | 0 | 0 |
| Withdrew: Voluntary withdrawal | 2 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 1 | 0 | 0 | 0 | 0 |
| Milestone | Induction Phase: Vedolizumab, 300 mg | Induction Phase: Placebo | Maintenance Phase: Vedolizumab 300 mg | Maintenance Phase: Placebo | Maintenance Phase: Placebo Continuation | Open-Label: Vedolizumab 300 mg |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 12 | 12 | 17 | 0 |
| Completed | 0 | 0 | 7 | 4 | 5 | 0 |
| Not completed | 0 | 0 | 5 | 8 | 12 | 0 |
| Withdrew: Pretreatment event/adverse event | 0 | 0 | 2 | 4 | 2 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 2 | 4 | 10 | 0 |
| Milestone | Induction Phase: Vedolizumab, 300 mg | Induction Phase: Placebo | Maintenance Phase: Vedolizumab 300 mg | Maintenance Phase: Placebo | Maintenance Phase: Placebo Continuation | Open-Label: Vedolizumab 300 mg |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 134 |
| Completed | 0 | 0 | 0 | 0 | 0 | 57 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 77 |
| Withdrew: Pretreatment event/adverse event | 0 | 0 | 0 | 0 | 0 | 43 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Voluntary withdrawal | 0 | 0 | 0 | 0 | 0 | 7 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 23 |
| Withdrew: Reason not specified | 0 | 0 | 0 | 0 | 0 | 2 |
A response to therapy is considered a decrease from baseline of at least 100 points in the CDAI score at Week 10. CDAI is scoring system for the assessment of Crohn's disease activity. The total CDAI score ranges from 0 to approximately 600, where higher scores indicate more severe disease. Index values of 150 and below are associated with quiescent disease; values above that indicate active disease.
| percentage of participants | Induction Phase: Vedolizumab, 300 mg | Induction Phase: Placebo |
|---|---|---|
| Induction Phase: Percentage of Participants With Crohn's Disease Activity Index (CDAI)-100 Response | 26.6 (17.268 to 37.720) | 16.7 (9.184 to 26.813) |
Clinical remission is defined as the CDAI score ≤150. CDAI is scoring system for the assessment of Crohn's disease activity. Index values of 150 and below are associated with quiescent disease; values above that indicate active disease.
| percentage of participants | Maintenance Phase: Vedolizumab 300 mg | Maintenance Phase: Placebo |
|---|---|---|
| Maintenance Phase: Percentage of Participants With Clinical Remission | 41.7 (15.165 to 72.333) | 16.7 (2.086 to 48.414) |
An Adverse event (AE) is defined as any untoward medical occurrence in a study participant who received a drug (including a study drug); it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug whether or not it is considered related to the drug. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug.
| Participants | Induction Phase: Vedolizumab, 300 mg | Induction Phase: Placebo | Maintenance Phase: Vedolizumab 300 mg | Maintenance Phase: Placebo | Maintenance Phase: Placebo Continuation | Open-Label: Vedolizumab 300 mg |
|---|---|---|---|---|---|---|
| Number of Participants Who Experienced at Least One or More Treatment-Emergent Adverse Events (TEAEs) | 49 | 42 | 9 | 10 | 12 | 130 |
Reported events on this outcome measure were "Weight Decreased".
| Participants | Induction Phase: Vedolizumab, 300 mg | Induction Phase: Placebo | Maintenance Phase: Vedolizumab 300 mg | Maintenance Phase: Placebo | Maintenance Phase: Placebo Continuation | Open-Label: Vedolizumab 300 mg |
|---|---|---|---|---|---|---|
| Number of Participants With TEAE Related to Body Weight (Weight Decreased) | 0 | 0 | 0 | 0 | 0 | 2 |
Vital signs included body temperature (axilla), sitting blood pressure (after the participant has rested for at least 5 minutes), and pulse (bpm). Reported events on this outcome measure were "Pyrexia", "Body temperature increased", "Hypertension", and "Orthostatic hypotension".
| Participants | Induction Phase: Vedolizumab, 300 mg | Induction Phase: Placebo | Maintenance Phase: Vedolizumab 300 mg | Maintenance Phase: Placebo | Maintenance Phase: Placebo Continuation | Open-Label: Vedolizumab 300 mg |
|---|---|---|---|---|---|---|
| Pyrexia | 3 | 1 | 0 | 1 | 1 | 19 |
| Body Temperature Increased | 1 | 0 | 0 | 0 | 0 | 0 |
| Hypertension | 0 | 0 | 1 | 0 | 0 | 1 |
| Orthostatic Hypotension | 0 | 0 | 0 | 0 | 0 | 1 |
Reported events on this outcome measure were "Bundle Branch Block Right".
| Participants | Induction Phase: Vedolizumab, 300 mg | Induction Phase: Placebo | Maintenance Phase: Vedolizumab 300 mg | Maintenance Phase: Placebo | Maintenance Phase: Placebo Continuation | Open-Label: Vedolizumab 300 mg |
|---|---|---|---|---|---|---|
| Number of Participants With TEAE Related to Electrocardiogram (ECG) [Bundle Branch Block Right] | 0 | 0 | 0 | 0 | 0 | 1 |
The laboratory values outside the range (Hemoglobin \<=7 g/dL, Lymphocytes \<500 /microL, White Blood Cell (WBC) \<2000 /microL, Platelets \<7.5 10\^4/microL, Neutrophils \<1000 /microL, Alanine Aminotransferase (ALT) (Glutamic Pyruvic Transaminase; GPT) \>3.0 U/L x upper limit of normal (ULN), Aspartate Aminotransferase (AST) (Glutamic Oxaloacetic Transaminase; GOT) \>3.0 U/L x ULN, Total Bilirubin \>2.0 mg/dL x ULN, Amylase \>2.0 (U/L) x ULN are considered markedly abnormal.
| Participants | Induction Phase: Vedolizumab, 300 mg | Induction Phase: Placebo | Maintenance Phase: Vedolizumab 300 mg | Maintenance Phase: Placebo | Maintenance Phase: Placebo Continuation | Open-Label: Vedolizumab 300 mg |
|---|---|---|---|---|---|---|
| Hemoglobin (g/dL) <=7 | 0 | 1 | 0 | 0 | 0 | 4 |
| Lymphocytes (/uL) <500 | 7 | 6 | 1 | 2 | 1 | 18 |
| WBC (/uL) <2000 | 0 | 0 | 0 | 0 | 0 | 1 |
| Platelets (10^4/uL) <7.5 | 0 | 0 | 0 | 0 | 0 | 1 |
| Neutrophils (/uL) <1000 | 0 | 0 | 0 | 0 | 0 | 1 |
| ALT (GPT) (U/L) >3.0 x ULN | 1 | 1 | 0 | 0 | 0 | 1 |
| AST (GOT) (U/L) >3.0 x ULN | 1 | 0 | 0 | 0 | 0 | 1 |
| Total Bilirubin (mg/dL) >2.0 x ULN | 0 | 0 | 0 | 0 | 0 | 4 |
| Amylase (U/L) >2.0 x ULN | 1 | 0 | 0 | 0 | 0 | 8 |
Clinical remission is defined as the CDAI score ≤150. CDAI is scoring system for the assessment of Crohn's disease activity. Index values of 150 and below are associated with quiescent disease; values above that indicate active disease.
| percentage of participants | Induction Phase: Vedolizumab, 300 mg | Induction Phase: Placebo |
|---|---|---|
| Induction Phase: Percentage of Participants With Clinical Remission | 17.7 (10.041 to 27.942) | 10.3 (4.533 to 19.213) |
| mg/dL | Induction Phase: Vedolizumab, 300 mg | Induction Phase: Placebo |
|---|---|---|
| Change from Baseline at Week 2 | 0.022 ± 2.1421 | -0.125 ± 2.8417 |
| Change from Baseline at Week 6 | -0.089 ± 2.0266 | 0.130 ± 2.1674 |
| Change from Baseline at Week 10 | -0.164 ± 2.2729 | 0.077 ± 2.8690 |
A response to therapy is considered a decrease from baseline of at least 100 points in the CDAI score at Week 10. CDAI is scoring system for the assessment of Crohn's disease activity. The total CDAI score ranges from 0 to approximately 600, where higher scores indicate more severe disease. Index values of 150 and below are associated with quiescent disease; values above that indicate active disease.
| percentage of participants | Maintenance Phase: Vedolizumab 300 mg | Maintenance Phase: Placebo |
|---|---|---|
| Maintenance Phase: Percentage of Participants With Crohn's Disease Activity Index (CDAI)-100 Response | 58.3 (27.667 to 84.835) | 8.3 (0.211 to 38.480) |
Durable clinical remission is defined as participants with CDAI score ≤ 150 at both Weeks 14 and 60. CDAI is scoring system for the assessment of Crohn's disease activity. The total CDAI score ranges from 0 to approximately 600, where higher scores indicate more severe disease. Index values of 150 and below are associated with quiescent disease; values above that indicate active disease.
| percentage of participants | Maintenance Phase: Vedolizumab 300 mg | Maintenance Phase: Placebo |
|---|---|---|
| Maintenance Phase: Percentage of Participants With Durable Clinical Remission | 33.3 (9.925 to 65.112) | 25.0 (5.486 to 57.186) |
Corticosteroid-free clinical remission is defined as participants using oral corticosteroids at baseline (Week 0) who discontinued corticosteroids and were in clinical remission (CDAI score ≤ 150) at Week 60. CDAI is scoring system for the assessment of Crohn's disease activity. The total CDAI score ranges from 0 to approximately 600, where higher scores indicate more severe disease. Index values of 150 and below are associated with quiescent disease; values above that indicate active disease.
| percentage of participants | Maintenance Phase: Vedolizumab 300 mg | Maintenance Phase: Placebo |
|---|---|---|
| Maintenance Phase: Percentage of Participants With Corticosteroid-free Clinical Remission | 40.0 (5.274 to 85.337) | 0.0 (0.000 to 70.760) |
| ug/mL | Induction Phase: Vedolizumab, 300 mg |
|---|---|
| Week 2 | 28.23 ± 11.018 |
| Week 6 | 21.01 ± 14.076 |
| Week 10 | 22.31 ± 14.049 |
| Week 14 | 12.24 ± 10.350 |
| ug/mL | Maintenance Phase: Vedolizumab 300 mg | Maintenance Phase: Placebo |
|---|---|---|
| Week 2 | 29.32 ± 13.880 | 30.54 ± 9.7495 |
| Week 6 | 25.19 ± 17.054 | 24.90 ± 14.490 |
| Week 10 | 26.24 ± 15.464 | 26.60 ± 15.642 |
| Week 14 | 11.20 ± 8.5793 | 13.72 ± 13.072 |
| Week 22 | 9.102 ± 6.1809 | 1.502 ± 2.8285 |
| Week 30 | 9.013 ± 6.8774 | 0.000 ± 0.0000 |
| Week 60 | 13.68 ± 4.2659 | 0.000 ± 0.0000 |
| Participants | Induction Phase: Vedolizumab, 300 mg |
|---|---|
| Week 0 | 1 |
| Week 10 | 1 |
| 16 Weeks After Last Administration | 0 |
| Participants | Maintenance Phase: Vedolizumab 300 mg | Maintenance Phase: Placebo |
|---|---|---|
| Week 0 | 0 | 0 |
| Week 10 | 0 | 0 |
| Week 30 | 0 | 2 |
| Week 60 | 0 | 1 |
| 16 Weeks After Last Administration | 0 | 0 |
| Participants | Open-Label: Vedolizumab 300 mg |
|---|---|
| Week 0 | 2 |
| Week 10 | 2 |
| Week 30 | 2 |
| Week 62 | 0 |
| Week 94 | 0 |
| 16 Weeks After Last Administration | 2 |
| Participants | Induction Phase: Vedolizumab, 300 mg |
|---|---|
| Week 0 | 0 |
| Week 10 | 1 |
| 16 Weeks After Last Administration | 0 |
| Participants | Maintenance Phase: Vedolizumab 300 mg | Maintenance Phase: Placebo |
|---|---|---|
| Week 0 | 0 | 0 |
| Week 10 | 0 | 0 |
| Week 30 | 0 | 2 |
| Week 60 | 0 | 1 |
| 16 Weeks After Last Administration | 0 | 0 |
| Participants | Open-Label: Vedolizumab 300 mg |
|---|---|
| Week 0 | 2 |
| Week 10 | 2 |
| Week 30 | 1 |
| Week 62 | 0 |
| Week 94 | 0 |
| 16 Weeks After Last Administration | 2 |
Collected over From Baseline up to 16 weeks after the last dose of study drug (Up to approximately 170 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Induction Phase: Vedolizumab, 300 mg | 0/79 (0%) | 8/79 (10.1%) | 17/79 (21.5%) |
| Induction Phase: Placebo | 0/78 (0%) | 10/78 (12.8%) | 19/78 (24.4%) |
| Maintenance Phase: Vedolizumab 300 mg | 0/12 (0%) | 2/12 (16.7%) | 9/12 (75%) |
| Maintenance Phase: Placebo | 0/12 (0%) | 4/12 (33.3%) | 7/12 (58.3%) |
| Maintenance Phase: Placebo Continuation | 0/17 (0%) | 2/17 (11.8%) | 12/17 (70.6%) |
| Open-Label: Vedolizumab 300 mg | 0/134 (0%) | 70/134 (52.2%) | 113/134 (84.3%) |
| Event | Induction Phase: Vedolizumab, 300 mg | Induction Phase: Placebo | Maintenance Phase: Vedolizumab 300 mg | Maintenance Phase: Placebo | Maintenance Phase: Placebo Continuation | Open-Label: Vedolizumab 300 mg |
|---|---|---|---|---|---|---|
| Crohn's diseaseGastrointestinal disorders | 2/79 | 10/78 | 1/12 | 2/12 | 1/17 | 35/134 |
| SubileusGastrointestinal disorders | 1/79 | 0/78 | 0/12 | 1/12 | 0/17 | 1/134 |
| Abdominal adhesionsGastrointestinal disorders | 0/79 | 0/78 | 1/12 | 0/12 | 0/17 | 1/134 |
| Erythema nodosumSkin and subcutaneous tissue disorders | 0/79 | 0/78 | 0/12 | 1/12 | 0/17 | 0/134 |
| CellulitisInfections and infestations | 0/79 | 0/78 | 0/12 | 0/12 | 1/17 | 0/134 |
| Intestinal obstructionGastrointestinal disorders | 1/79 | 0/78 | 0/12 | 0/12 | 0/17 | 4/134 |
| Anal abscessInfections and infestations | 1/79 | 0/78 | 0/12 | 0/12 | 0/17 | 4/134 |
| IleusGastrointestinal disorders | 0/79 | 0/78 | 0/12 | 0/12 | 0/17 | 3/134 |
| Intestinal stenosisGastrointestinal disorders | 0/79 | 0/78 | 0/12 | 0/12 | 0/17 | 3/134 |
| Anal fistulaGastrointestinal disorders | 0/79 | 1/78 | 0/12 | 0/12 | 0/17 | 2/134 |
| Event | Induction Phase: Vedolizumab, 300 mg | Induction Phase: Placebo | Maintenance Phase: Vedolizumab 300 mg | Maintenance Phase: Placebo | Maintenance Phase: Placebo Continuation | Open-Label: Vedolizumab 300 mg |
|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 11/79 | 11/78 | 4/12 | 4/12 | 4/17 | 55/134 |
| Crohn's diseaseGastrointestinal disorders | 0/79 | 5/78 | 0/12 | 0/12 | 2/17 | 27/134 |
| PyrexiaGeneral disorders | 0/79 | 0/78 | 0/12 | 1/12 | 1/17 | 19/134 |
| InfluenzaInfections and infestations | 0/79 | 0/78 | 0/12 | 0/12 | 0/17 | 16/134 |
| ConjunctivitisInfections and infestations | 0/79 | 0/78 | 0/12 | 0/12 | 2/17 | 0/134 |
| Dental cariesGastrointestinal disorders | 0/79 | 0/78 | 0/12 | 0/12 | 1/17 | 15/134 |
| AnaemiaBlood and lymphatic system disorders | 0/79 | 0/78 | 0/12 | 0/12 | 0/17 | 13/134 |
| Iron deficiency anaemiaBlood and lymphatic system disorders | 0/79 | 0/78 | 1/12 | 0/12 | 0/17 | 0/134 |
| DiarrhoeaGastrointestinal disorders | 0/79 | 0/78 | 0/12 | 1/12 | 1/17 | 0/134 |
| Abdominal pain upperGastrointestinal disorders | 0/79 | 0/78 | 0/12 | 1/12 | 0/17 | 9/134 |
All participants who entered in the induction phase.
| Age, Continuous(years) | Induction Phase: Vedolizumab, 300 mg | Induction Phase: Placebo | Total |
|---|---|---|---|
| Mean | 33.9 ± 12.25 | 32.6 ± 10.93 | 33.3 ± 11.60 |
| Sex: Female, Male(Participants) | Induction Phase: Vedolizumab, 300 mg | Induction Phase: Placebo | Total |
|---|---|---|---|
| Female | 28 | 26 | 54 |
| Male | 51 | 52 | 103 |
| Race and Ethnicity Not Collected(Participants) | Induction Phase: Vedolizumab, 300 mg | Induction Phase: Placebo | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(Participants) | Induction Phase: Vedolizumab, 300 mg | Induction Phase: Placebo | Total |
|---|---|---|---|
| Japan | 79 | 78 | 157 |
| Height(cm) | Induction Phase: Vedolizumab, 300 mg | Induction Phase: Placebo | Total |
|---|---|---|---|
| Mean | 166.3 ± 8.73 | 166.4 ± 7.97 | 166.4 ± 8.33 |
| Weight(kg) | Induction Phase: Vedolizumab, 300 mg | Induction Phase: Placebo | Total |
|---|---|---|---|
| Mean | 58.53 ± 14.095 | 55.03 ± 8.928 | 56.79 ± 11.906 |
| Body Mass Index (BMI)(kg/m^2) | Induction Phase: Vedolizumab, 300 mg | Induction Phase: Placebo | Total |
|---|---|---|---|
| Mean | 21.15 ± 4.942 | 19.81 ± 2.567 | 20.48 ± 3.989 |
| Duration of Crohn's Disease(years) | Induction Phase: Vedolizumab, 300 mg | Induction Phase: Placebo | Total |
|---|---|---|---|
| Median | 7.20 (0.3 to 27.8) | 8.35 (0.3 to 32.0) | 7.90 (0.3 to 32.0) |
8 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.
Ran from Jan 2014 to primary completion in Jan 2019, 59 months.
Results were first posted in Dec 2019, 10 months after primary completion.
Of 70 industry-sponsored phase 3 interventional studies under Crohn Disease, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 69. This study's 59 months is above that.
Counting every sponsor, half of 88 studies reached it within 49 months; a quarter within 36 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vedolizumab